View More Recent Stories

Mar 11, 2025 08:55AM Stifel Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Feb 25, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Feb 24, 2025 01:40PM Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT)
Feb 24, 2025 07:24AM Summit Therapeutics (SMMT) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
Feb 24, 2025 06:08AM Summit Therapeutics (SMMT) Tops Q4 EPS by 1c
Jan 21, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Jan 8, 2025 06:06AM Truist Securities Starts Summit Therapeutics plc (SMMT) at Buy
Dec 6, 2024 06:40AM Jefferies Starts Summit Therapeutics plc (SMMT) at Buy
Nov 18, 2024 07:29AM H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Nov 4, 2024 03:27AM JMP Securities Starts Summit Therapeutics plc (SMMT) at Market Outperform
Oct 31, 2024 06:44AM Summit Therapeutics plc (SMMT) PT Lowered to $44 at H.C. Wainwright
Oct 30, 2024 07:22AM Summit Therapeutics (SMMT) Tops Q3 EPS by 2c
Oct 4, 2024 08:57AM Summit Therapeutics (SMMT): FDA granted Fast Track designation for proposed use of ivonescimab in combination with platinum-based chemotherapy for the treatment of EGFRm NSCLC
Oct 4, 2024 06:36AM H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Sep 27, 2024 09:49AM Increasing unusual put option volume: ASHR PPL MT SATS SAVA GEHC IONQ SMMT
Sep 27, 2024 05:29AM Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
Sep 27, 2024 05:29AM Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
Sep 25, 2024 07:04AM Summit Therapeutics plc (SMMT) PT Raised to $40 at Stifel
Sep 23, 2024 05:40AM Increasing unusual call option volume: CYH XND LUNR TRU EXC SMMT FWRD FDX GRAB CEG
Sep 17, 2024 05:09AM Increasing unusual option volume: CNM MULN SMAR COMP IMAX SMMT TRU AZUL XLI EMB CARR
Sep 16, 2024 06:55AM Summit Therapeutics plc (SMMT) PT Raised to $45 at H.C. Wainwright
Sep 16, 2024 06:30AM Summit Therapeutics (SMMT) Reports Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC
Sep 16, 2024 05:49AM Increasing unusual put option volume: CARR SMMT TT PLCE VSAT ZI HTGC VLY FL APH
Sep 13, 2024 09:53AM Increasing unusual call option volume: SLQT IBKR SMMT ZION XME MU FRWD ORCL RH NGD
Sep 12, 2024 10:12AM Increasing unusual option volume: FULC WGO EWY SMMT CRC WOOF DBRG PNR FHN
Sep 12, 2024 06:31AM Summit Therapeutics (SMMT) Announces 10.35M Share Offering at $22.70/sh
Sep 10, 2024 05:18AM Summit Therapeutics (SMMT) call put ratio 1.6 calls to 1 put with focus on September 15 calls after lung cancer drug shows benefits
Sep 9, 2024 08:37AM BMO Capital Reiterates Outperform Rating on Merck (MRK)
Sep 9, 2024 08:10AM Summit Therapeutics plc (SMMT) PT Raised to $25 at Stifel
Sep 9, 2024 06:53AM Merck (MRK) Falls 5% Following Data from Summit Therapeutics (SMMT)
Sep 9, 2024 06:40AM Summit Therapeutics plc (SMMT) PT Raised to $30 at H.C. Wainwright
Sep 9, 2024 05:03AM Summit Therapeutics plc (SMMT) PT Raised to $19 at Citi
Sep 8, 2024 11:45AM Summit (SMMT): Ivonescimab Monotherapy Reduced Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC
Sep 3, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Aug 12, 2024 06:36AM H.C. Wainwright Starts Summit Therapeutics plc (SMMT) at Buy
Aug 6, 2024 09:12AM Summit Therapeutics (SMMT) Files for 22.22M Share Offering by Selling Stockholders
Aug 6, 2024 07:14AM Summit Therapeutics (SMMT) Misses Q2 EPS by 3c ; Provides Outlook
Jul 19, 2024 05:14AM Citi Opens 90-Day Upside Catalyst Watch on Summit Therapeutics plc (SMMT)
Jun 27, 2024 04:16PM Summit Therapeutics (SMMT) Appoints Jeff Huber to its Board
View More Recent Stories